According to the NCCN Guidelines for Pancreatic Adenocarcinoma (Version 2, 2021) (7), fluorouracil-based regimens can be considered for second-line treatment of pancreatic cancer after failure of gemcitabine + albumin-bound paclitaxel chemotherapy regimens. Here, ALB is linked to pancreatic neoplasm.